CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade BioMarin Pharmaceutical Inc - BMRN CFD

66.58
4.68%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024818 %
Charges from full value of position ($-4.72)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024818%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002596 %
Charges from full value of position ($0.49)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002596%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 69.85
Open 66.47
1-Year Change -17.32%
Day's Range 66.47 - 68.49
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 29, 2024 69.85 0.88 1.28% 68.97 70.50 68.97
Oct 28, 2024 70.05 0.35 0.50% 69.70 70.56 69.37
Oct 25, 2024 69.66 -0.49 -0.70% 70.15 70.91 69.47
Oct 24, 2024 70.35 0.69 0.99% 69.66 70.88 69.04
Oct 23, 2024 69.91 0.06 0.09% 69.85 70.29 69.32
Oct 22, 2024 70.39 0.95 1.37% 69.44 70.67 69.13
Oct 21, 2024 70.20 0.65 0.93% 69.55 70.72 69.26
Oct 18, 2024 69.84 0.43 0.62% 69.41 70.05 69.17
Oct 17, 2024 69.39 -0.57 -0.81% 69.96 70.11 69.29
Oct 16, 2024 70.07 0.10 0.14% 69.97 70.84 69.76
Oct 15, 2024 70.37 0.48 0.69% 69.89 70.46 69.43
Oct 14, 2024 70.08 -0.22 -0.31% 70.30 70.68 69.70
Oct 11, 2024 70.28 0.83 1.20% 69.45 70.51 69.04
Oct 10, 2024 69.77 0.34 0.49% 69.43 69.79 68.72
Oct 9, 2024 69.72 1.49 2.18% 68.23 69.88 68.19
Oct 8, 2024 68.45 0.33 0.48% 68.12 68.85 67.95
Oct 7, 2024 68.64 -0.24 -0.35% 68.88 69.09 68.19
Oct 4, 2024 69.43 1.48 2.18% 67.95 69.51 67.70
Oct 3, 2024 68.09 -0.86 -1.25% 68.95 69.50 68.00
Oct 2, 2024 69.59 0.45 0.65% 69.14 69.77 68.38

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioMarin Company profile

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.

Equity composition

Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.

Industry: Biopharmaceuticals

105 Digital Dr
NOVATO
CALIFORNIA 94949
US

News

US elections: Trump leads the polls, but tariff talk spooks investors

As the US elections get closer we look at how Trump’s tariff plans could affect markets.

15:02, 22 October 2024

Gold markets to trade

Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.

08:00, 21 October 2024

US earnings seasons off to a solid start as focus shifts to tech giants

The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.

14:31, 17 October 2024

ECB Preview: cooling growth and inflation call for another rate cut

Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.

12:41, 16 October 2024

Australian labour force data forecast to reveal stable jobs market

Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.

07:41, 15 October 2024

Applying fundamental and technical strategies to Gold Trading

Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.

08:00, 14 October 2024

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

People also watch

Gold

2,785.76 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0180%
Short position overnight fee 0.0097%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.53 Price
-0.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

71,964.90 Price
-0.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

20,437.30 Price
-0.640% 1D Chg, %
Long position overnight fee -0.0248%
Short position overnight fee 0.0026%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading